Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
  • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
  • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
  • C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
  • C07D311/24—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
  • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
  • C07C59/40—Unsaturated compounds
  • C07C59/76—Unsaturated compounds containing keto groups
  • C07C59/90—Unsaturated compounds containing keto groups containing singly bound oxygen-containing groups
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
  • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
  • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
  • C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
  • C07D261/18—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen

Definitions

• R R R and R are hydrogen atoms, and R is a hydrogen atom, a hydroxy, alkyl, alkoxy, oxyacetic or nitro group, a halogen atom such as chlorine, bromine, fluorine, or R is a hydrogen atom, R and R are a hydrogen atom, a hydroxyl group or methoxy group, R and R are a hydrogen atom or a methoxy group or R R and R are hydrogen atoms, R and R are a methoxyl group.
• R may be:
• a hydroxylated group the compounds of the Formula I then being S-phenyl-isoxazole-S-carboxylic acids; the invention also relates to the alkali metal salts of these acids such as sodium or potassium, the addition salts of these acids with organic bases such as N-methylpiperazine, the dialkylamines, particularly diethylamine, the dialkylaminoalkanes, the alkylpyridine group.
• a group R being a hydroxy-alkyl group-a substituted or unsubstituted hydrazine group of the type:
• --HNNHR R being a hydrogen atom, an alkyl, aryl or arylalkyl group-in the guanidine group:
• the compounds ofthe generalFormula 1 are useful compounds from the pharmacological point vof view because they possess a noteworthy salidiuretic activity, which 1s eq ual to or even superior to that of hydrochlorothiazide, to which there are added, for some of them, analgesic and sedative.
• the benzoylpyruvic acids of the general Formula II are prepared by means of the condensationprocess described by 'Claisen.
• the latter consists inparticular in reacting the corresponding substituted or unsubstituted acetophenone and ethyl oxalate'in the presence of sodium methylate in a solvent such as petrol ether or heptanei
• the compounds in which R represents a hydroxyl group are obtained by the action of hydroxylamineon the corresponding chromone-Z-earboxylic acid; the reaction is carried out under a reflux in a solvent with a high boiling point such as dimethylformamide in the presence of a sodum alcoholate in a suflicient quantity for the medium to be basic.
• the acid chloride dissolved in'dichlorethane is added cold to a solution of the chosen amine in water in the presence of an agent which is capable of taking up'the hydrochloric acid formed, such as sodium bicarbonate;
• the acid chloride (III)' is obtained-by the action of thionyl chloride on the acid in' dichlorethane, by heating the reaction mixture under a reflux until it dissolved.
• esters are prepared by the action of the acid chloride on the alcohol or amino-alcohol in dioxane at boiling point.
• the ester is obtained in the form of the hydrochloride which makes it possible to increase the solubility of the product in water.
• EXAMPLE III 5-(2,4-dimethoxyphenyl)-isoxazole-3-carboxylic acid To 12.6 g. (0.05 mole) of 2,4 dimethoxy-benzoylpyruvic acid dissolved in 100 mls. of 95 ethyl alcohol one adds 16 g. (0.15 mole) of sodium carbonate and 3.5 g. (0.05 mole) of hydroxylamine hydrochloride. The agitation of the mixture is continued for 24 hours at ambient temperature.
• the ethyl alcohol is distilled oil in vacuo. mls. of water are added to the residue, it is filtered and washed with water. After recrystallisation from water and acetone one obtains 14.3 g. of p-isopropyl-S-phenyl-isoxazole-3- carboxylic acid. Yield: 62%. M.P.: 131 C.
• EXAMPLE V o-Hydroxy-S-phenyl-isoxazole-3-carboxylic acid
• This acid can be prepared by two difierent methods.
• the first of these (method A) makes use as raw material of a benzopyronic heterocyclic compound (chromone-2- carboxylic acid) which, when reacted with hydroxylamine, undergoes an opening of the ring at the point of the hetero-atom, followed by cyclisation.
• the second method (method B) is analogous to that described in the preceding examples because it makes use of a salt of ortho-hydroxybenzoylpyruvic acid.
• diethylamine S-phenyl-isoxazole-carboxylate diethylamine p-methoxy-S-phenyl-isoxazole-carboxylate;
• diethylamine para-bromo-5-phenyl-isoxazole-carboxylate diethylamine para-bromo-5-phenyl-isoxazole-carboxylate
• diethylamine para-fiuoro-S-phenyl-isoxazole-carboxylate diethylamine para-bromo-5-phenyl-isoxazole-carboxylate
• diethylamine para-fiuoro-S-phenyl-isoxazole-carboxylate diethylamine para-bromo-5-phenyl-isoxazole-carboxylate
• diethylamine para-fiuoro-S-phenyl-isoxazole-carboxylate diethylamine para-bromo-5-phenyl-isoxazole-carboxylate
• diethylamine para-fiuoro-S-phenyl-isoxazole-carboxylate
• diethylamine 3,4-dimethoxyphenyl-isoxazole-carboxylate diethylamine 2,4-dimethoxyphenyl-isoxazole-carboxylate.
• the residue is diluted with a solution of sodium bicarbonate; the mixture is treated several times with ether and ether solutions are washed with bicarbonate solution. The ether is distilled off until the residue is dry.
• EXAMPLE XVI Measurement of the diuretic activity The method used is a modification of that of Lipschitz and co-Workers (W. L. Lipschitz, Z. Haddian, A. Kerpscar, Bioassay of diuretics, J. Pharmacol, 1943, 79, 97- 100) by Gharib and co-workers (C. Gharib and co- The urine is collected every hour for six hours. The volume of urine excreted is measured and the chlorides and SOdllll'Il are determined.
• an irritant phenylbenzoquinone, in a 0.02% solution, into the peritoneum of the mouse, determines stretching or torsional movements.
• the operation is carried out on a batch of controls and on a batch of mice to which compound No. 19 according to Example XI is administered at a dosage rate of 300 mg./kg. per os, 30 minutes prior to injection with the irritant.
• mice out of 10 carried out less than 5 torsions in 5 minutes and are regarded as protected.
• This compound therefore possesses an analgesic eifect.
• EXAMPLE XVIII Measurement of the sedative action-actimeter test The modified Dews method is used (P. B. Dews, Brit. J. Pharmacol, 1953, vol. 8, p. 46) (I. R. Boissier, P. Simon, Arch. int. pharmacodyn. 1965, vol. 158, p. 212; J. R. Boissier, P. Simon and I. P. Tillement, Thrapie, 1966, vol. 21, p. 967).
• the neuroleptic activity is evaluated in the mouse.
• the animals are placed separately in cages through which there pass intersecting beams of infrared light falling on photo-electric cells. Actimeters make it possible to total the number of light rays traversed by the animal in each cage and in this way to assess the motor activity.
• the substance to be tested is administered per os. Chlorpromazine is used as a reference substance.
• the number of light beams passed through in minutes is:
• this compound When used in suflicient doses, this compound possesses a sedative activity comparable with that of chlorpromazine.
• EXAMPLE XIX Potentialisation of the narcosis induced with mebubarbital-hypno-sedation test A test is made to find whether the administration by gastric probe to the mouse of compounds forming the subject of the invention prolongs the mean time of sleep induced by the injection of mebubarbital. Chlorpromazine is used as reference substance.
• the sleeping time is:
• compound No. 20 brings about an increase in the contractile force of the heart and a fall in the general arterial pressure.
• This compound the toxicity of which is particularly low (LD 0 higher than 1,200 mg./kg.-po in the mouse) possesses remarkable analeptic, cardiac and hypotensive properties both in the animal with normal tension and that with hypertension.
• the daily doses will be from 3 to 4 tablets possessing the above composition.
• the daily doses will be from 3 to 4 capsules possessing the above composition.
• the daily doses are 5 mls. in subcutaneous or intramuscular injections.
• EXAMPLE XXIV A 50-year-old patient was hospitalised in a condition of asystole, with cardiac oedema, enlargement of the liver, pleural effusion.
• the diuretic effect was considerable for the first 3 injections, but then became less.
• the secretion of sodium in the urine was distinct during the first few days. The clinical improvement was satisfactory.
• R1 -COR 1 6 selected from the group consisting of a pyridyl group and a C -C picolyl group.
• the carboxylic acid of claim 1 p-chloro-S-phenyl-(4'-pyridine)-propyloxy 3 carbonylisoxazole. 3.
• the carboxylic acid of claim 1 5(3,4-dimethoxy-phenyl) 3-(3' pyridine methoxycarbonyl isoxazole. 4.
• the carboxylic acid of claim 1 p-chloro-S-phenyl 3(4 pyridine-methoxycarbonyl)- isoxazole.

Applications Claiming Priority (1)

Publications (1)

Family

ID=9045027

Family Applications (1)

Country Status (11)

Cited By (10)

Families Citing this family (7)

Family Cites Families (2)

• 1969
  • 1969-12-23 FR FR696944556A patent/FR2073284B1/fr not_active Expired
• 1970
  • 1970-11-30 GB GB5678270A patent/GB1337280A/en not_active Expired
  • 1970-12-01 ES ES386068A patent/ES386068A1/es not_active Expired
  • 1970-12-02 US US00094527A patent/US3752819A/en not_active Expired - Lifetime
  • 1970-12-18 DE DE2065430A patent/DE2065430A1/de active Pending
  • 1970-12-18 DE DE19702062373 patent/DE2062373A1/de active Pending
  • 1970-12-18 CH CH1882370A patent/CH546252A/fr not_active IP Right Cessation
  • 1970-12-22 AR AR233107A patent/AR192303A1/es active
  • 1970-12-22 LU LU62295D patent/LU62295A1/xx unknown
  • 1970-12-22 BE BE760711A patent/BE760711A/fr unknown
  • 1970-12-23 JP JP45117333A patent/JPS4927585B1/ja active Pending
  • 1970-12-23 NL NL7018727A patent/NL7018727A/xx unknown
• 1972
  • 1972-01-21 JP JP47008234A patent/JPS4917260B1/ja active Pending
  • 1972-06-30 JP JP47066221A patent/JPS4917261B1/ja active Pending

Also Published As

Similar Documents